News

UAB’s new Clinical Trialist Development Program (CTDP) has selected 24 Heersink applicants for its 2026-2027 cohort. The program will provide these candidates with training, mentorship, and salary support to lead industry-sponsored clinical trials. It will also supply them with a 20% protected time allowance, allowing them to dedicate more time to research.

The UAB Medicine Leadership Development Office (LDO) recently recognized 11 individuals in its ninth cohort of its LEading, Advancing, Developing (LEAD) program. The fall 2026 graduates received their certificates on Sept. 3.

The Southeastern Biosafety Laboratory Alabama Birmingham (SEBLAB) at UAB is one of 12 Regional Biocontainment Laboratories funded by the National Institute of Allergy and Infectious Disease.

The UAB Medicine Leadership Development Office (LDO) is proud to honor the latest graduates of the Emerging Leaders Series (ELS) — 24 accomplished professionals who represent the breadth and strength of our institution.

In May 2025, after more than 30 years at The University of Iowa, John Engelhardt, Ph.D., packed up his laboratory and traveled 881 miles to Birmingham to begin a new chapter in advancing cystic fibrosis (CF) and drug development research at UAB.

Four projects have been selected as the inaugural awardees of the Dr. Latesha E. Elopre Health Across the Lifecourse (HEAL) Pilot Program, supporting innovative research designed to improve health outcomes across the lifespan.

The UAB Mary Heersink Institute for Global Health, in conjunction with the UAB Marnix E. Heersink Institute for Biomedical Innovation, proudly announces the fifth cohort of pilot grant awardees.Four innovative projects have received pilot funding to encourage collaboration between UAB investigators and international partners, tackling critical global health challenges.

Do you have COPD? Are you 40 – 80 years old?

ZION is a clinical research study for adults with chronic obstructive pulmonary disease (COPD). This study will test a study drug injection to learn about its safety, effectiveness, and tolerability (side effects) in participants with COPD.

In partnership with the Housing Authority of the Birmingham District, the City of Birmingham and community partners, UAB will assess the effectiveness of public housing renovations and environmental refinements on community health.

UAB Medicine’s Leadership Development Office (LDO) honored 33 graduates of the Emerging Leaders Series (ELS) fall 2025 Cohort 4 during a ceremony held on Thursday, Nov. 12. The cohort completed a multi-session program designed to strengthen leadership capability for emerging leaders across the enterprise.

Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a rare, but serious, genetic disorder that causes abnormal blood vessels to form throughout the body. These abnormal vessels bypass much smaller blood vessels, or capillaries, creating direct connections between arteries and veins known as arteriovenous malformations (AVMs).

The UAB Heersink School of Medicine is proud to announce the recipients of the 2024/2025 Multi-PI Awards, each funded with $150,000 per year for two years. These awards recognize outstanding collaborative research efforts aimed at addressing critical health challenges.

UAB is combating youth tobacco use with its ninth annual award from the Alabama Department of Public Health.

The UAB Lung Health Center has received a grant from the Alabama Department of Public Health to support smoking and vaping prevention efforts among middle and high school students in the Birmingham area.

Opportunity to quit smoking cigarettes. Fully remote.

One Breath Matters.Are you or someone you care about age 25-35 and interested in lung health?

Women who have never smoked have smaller lung airways than men do, leading to higher risk for COPD.

If you have asthma, are at least 18 years of age, in the Los Angeles Region, (California) haven’t had oral steroids in at least 4 weeks, and are willing to donate 30 mL of blood, equivalent to two tablespoons, please contact Racheal Ogbebor at email Rachealogbebor@gmail.com.

Record $95 million Heersink lead gift to advance strategic growth and biomedical innovation.